// App-Quantinova.ai

e17049 : A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.

Researchers

Presenter

  • Jason D. Lickliter

Principal Investigators

  • Hui Kong Gan

  • Tarek Meniawy

  • Jason Yang

  • Lai Wang

  • Lusong Luo

  • Ni Lu

  • Michael Millward

Medical Centers

  • Nucleus Network, Melbourne, Australia

  • Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Australia

  • Sir Charles Gairdner Hospital, Perth Western Australia, Australia

  • BeiGene (Beijing) Co., Ltd., Beijing, China

  • BeiGene (Beijing) Co., Ltd., Beijing, China

  • Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands, Australia

Locations

  • China

  • Australia

Companies

  • BeiGene (Beijing) Co

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Poly(ADP-Ribose) Polymerase 1

Drug/Treatment

  • BGB-290

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02361723

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved